> Detailanzeige

Buske, Christian; Dreyling, Martin H.; Eimermacher, Hartmut; Boeck, Hans-Peter; Pfreundschuh, Michael; Metzner, Bernd; Fuchs, Roland; Woermann, Bernhard; Truemper, Lorenz H.; Hess, Georg; Wandt, Hannes; Ludwig, Wolf-Dieter; Kreuser, Ernst-Dietrich; Schimke, Joerg; Weh, H.-J.; Schmitz, Stephan; Schmiegel, W.; Unterhalt, Michael; Hiddemann, Wolfgang

Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
  • Beteiligte: Buske, Christian; Dreyling, Martin H.; Eimermacher, Hartmut; Boeck, Hans-Peter; Pfreundschuh, Michael; Metzner, Bernd; Fuchs, Roland; Woermann, Bernhard; Truemper, Lorenz H.; Hess, Georg; Wandt, Hannes; Ludwig, Wolf-Dieter; Kreuser, Ernst-Dietrich; Schimke, Joerg; Weh, H.-J.; Schmitz, Stephan; Schmiegel, W.; Unterhalt, Michael; Hiddemann, Wolfgang
  • Erschienen: American Society of Hematology, 2004
  • Erschienen in: Blood, 104 (2004) 11, Seite 162-162
  • Sprache: Englisch
  • DOI: 10.1182/blood.v104.11.162.162
  • ISSN: 0006-4971; 1528-0020
  • Schlagwörter: Cell Biology ; Hematology ; Immunology ; Biochemistry
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Abstract Lymphomplasmocytoid/ic immunocytoma (LP-IC), including Waldenstrom’s macro-globulinemia and lymphoplasmacytoid lymphoma according to the Kiel classification (the latter one subsummed as a variant of B-CLL in the WHO classification), is an indolent lymphoma, which is incurable by conventional chemotherapy in the advanced stage of disease. The anti-CD20 antibody Rituximab has shown remarkable activity in indolent lymphomas, in particular when combined with chemotherapy. Based on these results the GLSG investigated the efficacy of a combined immuno-chemotherapy (R-CHOP: Rituximab 375 mg/m2 d0-1; cyclophosphamide 750 mg/m2 d1; doxorubicine 50 mg/m2 d1; vincristine 1.4 mg/m2 d1; prednisone 100 mg/m2 d1-5) versus CHOP alone as first line treatment of LP-IC in a multicenter prospective randomized phase III trial. Of 72 patients 71 % were classified as lymphoplasmacytic lymphoma, 29 % as lymphoplasmocytoid subtype by central pathology review. The median age was 61.5 years (60 years for R-CHOP and 62 years in the CHOP arm); 24% of the patients had an IPI score >2. The overall response (OR) rate was significantly improved by combining Rituximab with CHOP compared to CHOP alone with an OR of 94% (11% CR, 83% PR) for R-CHOP and an OR of 69% (3% CR, 67% PR) for CHOP (p=0.012). Furthermore, patients treated with R-CHOP showed a significantly prolonged time to treatment failure (TTF) with an estimated median TTF of 22 month in the CHOP arm, whereas the median was not reached in the immunochemotherapy arm after a maximum follow up of nearly 4 years (p=0.0057). There was no major difference of the toxicity in both treatment groups. In summary, these data indicate a beneficial effect of combined immunochemotherapy (R-CHOP) as compared to CHOP alone with regards to initial cytoreduction as well as TTF in patients with LP-IC in a prospective randomized trial, establishing R-CHOP as an highly attractive regimen for first line treatment of this distinct lymphoma subtype.
  • Zugangsstatus: Freier Zugang